For instance, it remains unknown whether FSP1 or DHODH compensates for GPX4 deficiency in RCC subtypes [e.g., ccRCC with GPX4 silencing (227)] or if their dysregulation contributes to ferroptosis resistance; this limits the development of pan-ferroptosis targeting strategies. This evidence concerns the gene AIFM2 and renal cell carcinoma.